Freestone Capital Holdings’s Idexx Laboratories IDXX Stock Holding History

Freestone Capital Holdings’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,586	Closed	-$1.07M	–	600
2025 Q4	$1.07M	Buy	1,586 +399	+34%	+$272K	0.03%	235
2025 Q3	$758K	Buy	+1,187	New	+$720K	0.02%	276
2022 Q3	–	Sell	-629	Closed	-$221K	–	405
2022 Q2	$221K	Sell	629 -201	-24%	-$82K	0.01%	376
2022 Q1	$454K	Buy	830 +131	+19%	+$68.9K	0.02%	372
2021 Q4	$460K	Buy	699 +25	+4%	+$15.7K	0.02%	330
2021 Q3	$419K	Buy	674 +150	+29%	+$101K	0.02%	306
2021 Q2	$331K	Buy	524 +26	+5%	+$14.4K	0.02%	323
2021 Q1	$244K	Buy	498 +117	+31%	+$58.6K	0.01%	358
2020 Q4	$190K	Buy	381 +89	+30%	+$39.8K	0.01%	352
2020 Q3	$115K	Buy	+292	New	+$108K	0.01%	384

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Freestone Capital Holdings's IDXX Position: Q1 2026 in Review

Freestone Capital Holdings sold out of Idexx Laboratories (IDXX) in Q1 2026, closing a stake of 1,586 shares — an estimated $1.07M sold.

Freestone Capital Holdings first reported a position in IDXX in Q3 2020 and held it in 10 quarters. The position peaked at $1.07M in Q4 2025. 1,314 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Freestone Capital Holdings reported no remaining Idexx Laboratories position as of Q1 2026 after selling out during the quarter.
Freestone Capital Holdings sold 1,586 Idexx Laboratories shares in Q1 2026, an estimated $1.07M.
Freestone Capital Holdings first reported a position in Idexx Laboratories in Q3 2020 and held it in 10 quarters.
Freestone Capital Holdings's Idexx Laboratories position peaked at $1.07M in Q4 2025.
1,314 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Freestone Capital Holdings's 13F filing for Q1 2026, filed 13 May 2026.